A recent study published by Auburn University scientists has made a breakthrough in Alzheimer’s disease research, showing that troriluzole can prevent early-stage brain changes associated with memory loss and cognitive decline in mice. The researchers demonstrated that troriluzole reduces harmful glutamate levels, preserving memory and cognitive function.
The study, recently published in the Journal of Neurochemistry, is the first to show how troriluzole targets early-stage alterations associated with Alzheimer’s disease, offering new hope for potential treatments. Dr. Miranda Reed, a Professor at Auburn University, noted that “by examining how drug treatments can intervene early in the disease process, we aim to develop therapies that might prevent or even cure Alzheimer’s.”
Troriluzole works by reducing synaptic glutamate levels and decreasing brain hyperactivity, leading to improved cognitive abilities. The treated mice performed better in memory tests, such as navigating mazes, indicating that their cognitive functions were restored.
The study was a collaborative effort involving Auburn University’s College of Science and Mathematics, the Harrison College of Pharmacy, and the Center for Neuroscience Initiative, along with private researchers and students. The team’s combined expertise in neuroscience and pharmacology was crucial to the study’s success.
While the results in mice are encouraging, the researchers emphasize the need for further studies to determine how troriluzole works at different stages of disease progression.
Source: https://neurosciencenews.com/neuropharmacology-trotiluzole-alzheimers-27604/